Orexo Ab · OMXSTO:ORX
Orexo Ab — Erik Penser Bolagsdag 2020
26 slides from Orexo Ab's conference presentation, Jun 4, 2020
Slide 1: Erik Pensers Bolagsdag
Develops and commercializes improved pharmaceuticals and digital therapies in the growing space of substance use disorders and mental health Erik Pensers Bolagsdag Nikolaj Sørensen, President and CE0, June 4, 2020 1
Slide 2: Legal Disclaimer
Legal Disclaimer • This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) (“Orexo”) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Orex
Slide 3: Overview & strategic agenda
Overview & strategic agenda
Slide 4: Orexo develops and commercializes pharmaceuticals and digital therapies
Orexo develops and commercializes pharmaceuticals and digital therapies • Addresses unmet needs within the growing space of Corporate Headquarters (Uppsala, Sweden) substance use disorders (SUD) and mental health Corporate functions and • Broad product portfolio and development pipeline of tradition
Slide 5: 2012 – 2019 successful strategic focus on building a solid foundation
2012 – 2019 successful strategic focus on building a solid foundation EBITDA SEK m 2012-2019 300 SEK 817m Cash position Launch Zubsolv® in the US 250 (Q120 200 SEK 861 m) 150 First actions taken to broaden the US commercial platform 100 50 2012 Secure profitability 0 2019 -50 Ensure a sustaina
Slide 6: The profit and cash contributions from Zubsolv enables continued investments
The profit and cash contributions from Zubsolv® enables continued investments in building a broader and stronger Orexo Broaden… Establish ..the portfolio of commercial products to be ..a new revenue generating business area promoted by our existing US organization in within Digital Therapeutics (DTx
Slide 7: Product portfolio
Product portfolio
Slide 8: Product portfolio including upcoming US launches in 2020
Product portfolio including 3 upcoming US launches in 2020 Product Zubsolv® deprexis® vorvida® Abstral® Edluar® Indication Opioid use disorder Symptoms of mild Alcohol misuse Breakthrough Sleeping (OUD) to severe incl. alcohol use cancer pain disorder depression disorder (AUD) Key market US US US As
Slide 9: COVID-19 has significantly raised awareness and demand for digital therapies
COVID-19 has significantly raised awareness and demand for digital therapies, particularly in certain conditions such as SUD and mental health issues March 2020 April 2020 Patients are US outbreak flooding to surges, virtual clinics and online medical Isolation councils consequences appearing as Com
Slide 10: Orexo's partner GAIA is a world leader in developing digital therapies
Orexo´s partner GAIA is a world leader in developing digital therapies ” GAIA is a global pioneer in digital therapeutics, successfully launching its first product in 2001 • GAIA has demonstrated digital therapies can have impressive improvement in treatment outcomes from supporting behavioral chang
Slide 11: With digital therapies, Orexo is well positioned to take a leading role
With 3 digital therapies, Orexo is well positioned to take a leading role addressing unmet needs within SUD and mental health issues……. One of the most researched digital therapies deprexis® in the world deprexis® is a fully automated digital therapy to • Effectiveness in managing the symptoms help
Slide 12: Digital therapies with scientifically proven efficacy
……..offering digital therapies with scientifically proven efficacy enabling patients to receive help while maintaining social distancing vorvida® OXD01 A fully automated digital therapy scientifically “Digitizing” counselling at scale to offer with proven to reduce trouble-some drinking patterns in
Slide 13: Zubsolv has grown YoY despite increasing competition
Zubsolv® has grown YoY despite increasing competition US Net Revenues US Operating Profit USD million USD million 76 37 71 40 30 56 57 22 49 20 11 33 10 5 - (10) 1 (10) (14) (12) (20) 2013 2014 2015 2016 2017 2018 2019 2013 2014 2015 2016 2017 2018 2019 7 10 13 17 20 19 23 (14) (26) (36) (31) (19) 3
Slide 14: Market growth of 15% YTD vs prior year is the strongest since Zubsolv launch
Market growth of 15% YTD vs prior year is the strongest growth rate since Zubsolv® launch Market Volume Sales Q1 YTD Growth Quarterly NTRx Total Market: +15% 2 000 000 By Segment 1 800 000 Open +15% 1 600 000 Non-reimbursed +15% 1 400 000 1 200 000 Definitions Payers / Market Access 1 000 000 • “Ope
Slide 15: Open segment becomes an important growth driver
Open segment becomes an important growth driver, when the decline in UHC and Humana diminish in 2020 Q1 YoY Growth Zubsolv by Access Segments R4W Average NTRx in Bold Color; Single Week NTRx in Lighter Shade Zubsolv® 1/3 week 6106,4 5778,3 5889,7 Open 8% 4433,7 3928,4 3648,5 UHC/Humana/C -28% ash 16
Slide 16: Zubsolv growth in open business explained by unrestricted access to PBMs
Zubsolv® growth in open business explained by unrestricted access to all large national commercial PBMs Prescription incremental growth to major national PBMs Zubsolv NTRx YoY Q1 Total increase of 4,162 NTRx YoY 3 364 Opportunity to continue to grow business and to translate successes to other payer
Slide 17: Several possible triggers for Zubsolv growth in 2020 and beyond
Several possible triggers for Zubsolv® growth in 2020 and beyond Continued improved market access …Orexo continues to aggressively pursue expanding market access in Medicare and Medicaid …Largest branded competitor likely to lose reimbursement over time Competition from “the preferred” authorized ge
Slide 18: Development projects
Development projects
Slide 19: 3 convincing development assets addressing critical unmet needs
3 convincing development assets addressing critical unmet needs OX124 – opioid overdose OX125 – opioid overdose OX338 – non-opioid pain A powerful rescue A rescue medication to A non-opioid pain killer medication, designed to reverse opioid overdoses, with opioid-level efficacy reverse opioid overdo
Slide 20: OX124 - Deaths from synthetic opioids continue to rise
OX124 - While overall deaths from opioid overdoses showed a slight decline in 2018, deaths from synthetic opioids continue to rise Deaths from opioid overdose By type of opioid, United States 50 000 Any opioid 45 000 40 000 35 000 30 000 Synthetic opioids 25 000 Deadly dose comparison 20 000 15 000
Slide 21: OX124 - Better PK profile than Narcan Nasal Spray
OX124 - We have shown better PK profile than Narcan® Nasal Spray Faster, stronger and longer-acting vs Narcan® Nasal Spray Expected patient benefit Results from exploratory PK study in healthy volunteers, 2019 Plasma OX124 • Rescue more patients with concentration Narcan Nasal Spray the first dose (
Slide 22: Financials & outlook
Financials & outlook
Slide 23: Strong financial position enabling continued investments in future growth
Strong financial position enabling continued investments in future growth opportunities Group net revenues LTM Growth SEK 846 m 3% Of which 85% from Zubsolv® US Zubsolv® US 11% Group EBITDA LTM Growth SEK 299 m 133% US Pharma EBIT (Zubsolv® US) LTM Growth SEK 355 m 50% Cash position Positive net cas
Slide 24: Limited impact from the COVID-19 disease currently
Limited impact from the COVID-19 disease currently1 Development Supply Sales Finance OX125 – First clinical Zubsolv® - Manufacturing Zubsolv®, vorvida®, Orexo has SEK 861 m in phase 1 study initated of Zubsolv® is solely done in deprexis® - Sales calls have cash and a profitable according to plan in
Slide 25: 2020 a year with a steady news flow expected
2020 a year with a steady news flow expected Q2 Q3 Q4 › FDA clearance of vorvida® › Launch of deprexis® › Initiation of OX124 pivotal › Patent for nasal spray › Launch of vorvida® trial technology › FDA decision on fast track › Potential launch of OXD01 › OX125 exploratory study designation of OX124
Slide 26: THANK YOU!
THANK YOU! IR Contact: Lena Wange, IR & Communications Manager, ir@orexo.com. For more information please visit www.orexo.com. You can also follow Orexo at Twitter @orexoabpubl, LinkedIn and YouTube